FindTrial
Sign In

Effect of 12 Weeks Practice of Anulom Vilom Pranayama as Adjunctive Therapy for Drug Resistant Epilepsy

Effect of 12-Weeks Practice of Anulom Vilom Pranayama (Alternate Nostril Breathing) as Adjunctive Therapy on the Cardiac Autonomic Status, Psychological Status, Cognition and Quality of Life in Individuals with Drug-Resistant Epilepsy - A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094792
Enrollment
88
Registered
2025-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G408- Other epilepsy and recurrent seizures

Interventions

Intervention1: Structured Anulom Vilom Pranayama will be given as adjunctive therapy to conventional therapy for patients with Drug-Resistant Epilepsy: Pranayama therapy will be introduced to particip

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinically diagnosed drug resistant epilepsy Both gender, age from 18 years to 45 years

Exclusion criteria

Exclusion criteria: Poorly controlled chronic cardiovascular, respiratory or other neurological comorbidities. Advanced dementia or other unstable medical illnesses that may prevent the active participation of the study participants in the various study procedures. Patients with current active infections, such as tuberculosis. Comorbid autoimmune diseases. Pre-existing endocrine, hepatic, renal and connective tissue disorders and malignancies. Individuals with a history of chronic alcoholism and/or substance abuse. Pregnant and lactating women. Patients who are unable to read/understand or communicate Tamil/English language. Individuals who are already practicing some form of structured pranayama or yoga on a regular basis will also be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Cardiac sympathovagal balance - LF:HF ratioTimepoint: Baseline (0 weeks) and at the end of 12 weeks—

Secondary

MeasureTime frame
a) Heart Rate Variability indices other than LF: HF(Time domain and frequency domain indices) b) Baroreflex Sensitivity(BRS) c) Cognition (P300, Auditory reaction time, Visual reaction time) d) Psychological status (DASS-21, PANAS-SF) e) Biochemical markers of neuroinflammation (Interleukin -6) f) Quality of life (QOLIE -31) g) Seizure frequencyTimepoint: Change in these study parameters from 0 week (baseline) to the end of 12 weeks—

Countries

India

Contacts

Public ContactMs Subiksha SR

Jawaharlal Institute of Postgraduate Medical Education and Research

subiksha7901@gmail.com7397113106

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026